A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs

The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.

Trial Details

NCT ID
NCT07905183
Phase
PHASE3
Sponsor
Enliven Therapeutics
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ELVN-001
  • TKI
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Morristown, New Jersey, United States|40.79677,-74.48154
  • Ogden, Utah, United States|41.223,-111.97383

Key Eligibility Criteria

  • Male or female at least 18 years of age
  • Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
  • Prior treatment with 1 or more BCR::ABL1 TKI(s)
  • Failure or intolerance on the immediate prior TKI

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →